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ABSTRACT 
Purpose: To determine the molecular genetic cause in previously unreported probands with 
optic atrophy from the United Kingdom, Czech Republic and Canada. 
Methods: OPA1 coding regions and flanking intronic sequences were screened by direct 
sequencing in 82 probands referred with a diagnosis of bilateral optic atrophy. Detected rare 
variants were assessed for pathogenicity by in silico analysis. Segregation of the identified 
variants was performed in available first degree relatives. 
Results: A total of 29 heterozygous mutations evaluated as pathogenic were identified in 42 
probands, of these 7 were novel. In two probands only variants of unknown significance were 
found. 76% of pathogenic mutations observed in 30 (71%) out of 42 probands were evaluated 
to lead to unstable transcripts resulting in haploinsufficiency. Three probands with the 
following disease-causing mutations c.1230+1G>A, c.1367G>A and c.2965dup were 
documented to suffer from hearing loss and/or neurological impairment.  
Conclusions: OPA1 gene screening in patients with bilateral optic atrophy is an important 
part of clinical evaluation as it may establish correct clinical diagnosis. Our study expands the 
spectrum of OPA1 mutations causing dominant optic atrophy and supports the fact that 
haploinsufficiency is the most common disease mechanism.  
 
Keywords: dominant optic atrophy, OPA1, novel mutations, haploinsufficiency, DOA plus 
syndrome  
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INTRODUCTION 
Autosomal dominant optic atrophy (DOA, OMIM 165500) is the most prevalent hereditary 
optic neuropathy with an estimated prevalence of 1:12,000 - 1:50,000 (Lyle 1990; Kjer et al. 
1996). The disease is genetically heterogeneous, with five mapped loci (Votruba et al. 1997; 
Kerrison et al. 1999; Anikster et al. 2001; Barbet et al. 2005; Carelli et al. 2011). To date 
however only two genes have been identified as disease-causing: optic atrophy gene 1 (OPA1; 
MIM 165500) (Alexander et al. 2000; Delettre et al. 2000) and optic atrophy gene 3 (OPA3; 
MIM 606580) (Anikster et al. 2001; Reynier et al. 2004). OPA1 is the most frequently 
mutated gene causing DOA accounting for up to 60% of cases with inherited optic atrophies 
(Yu-Wai-Man et al. 2009). 
DOA shows highly variable expression, onset and progression. In most patients the disease 
manifests by the end of the first decade of life. Typically, loss of central vision, optic nerve 
pallor, a centro-caecal scotoma and color vision deficit are observed (Votruba et al. 1998; 
Rönnbäck et al. 2015). In some individuals DOA plus phenotype is found; characterized by 
variable presence of sensorineural hearing loss, ataxia, axonal sensory-motor polyneuropathy, 
multiple sclerosis-like phenotype, chronic progressive external ophthalmoplegia and 
mitochondrial myopathy (Amati-Bonneau et al. 2009; Yu-Wai-Man et al. 2010; Liskova et al. 
2013). Most recently association of OPA1 mutations with a multi system disorders 
characterized by age-related parkinsonian features as well as cognitive deterioration has been 
described (Carelli et al. 2015). 
The OPA1 protein is a mitochondrially targeted dynamin-related GTPase located on the inner 
mitochondrial membrane functioning mainly in mitochondrial fusion and regulation of 
apoptosis (Cho et al. 2010). Initial studies suggested that OPA1 dysfunction leads to primary 
retinal ganglion cell degeneration (Olichon et al. 2007), however recent evidence propose that 
more diverse mechanisms are implicated in the disease pathogenesis (Bertholet et al. 2013). 
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The aim of our study was to explore the involvement of OPA1 mutations in a large cohort of 
probands with bilateral optic atrophy. 
 
MATERIAL AND METHODS 
Patients 
In this study we have included samples of 81 probands of white British, Canadian and Czech 
origin and one proband of Czech Roma origin; referred with the diagnosis of bilateral optic 
atrophy to the All Wales Genetic Testing Service; University Hospital of Wales and General 
University Hospital in Prague for laboratory investigation. The study followed the tenets of 
the Declaration of Helsinki and was authorized by local Ethical boards. All investigated 
individuals signed informed consent. 
Clinical referral notes of the patients indicated bilateral impairment of best corrected visual 
acuity, pallor of the optic nerve head, evidence of colour vision deficit and no evidence of 
other factors causing compressive or optic neuropathy. In some probands but not all clinical 
data included also family history for optic atrophy and results of neurological and audiometry 
examinations.  
 
Molecular genetic analysis 
Prior to the start of the study participating probands were tested negative for the three most 
prevalent mitochondrial mutations associated with Leber hereditary optic atrophy (Yu-Wai-
Man et al. 2011). Positive family history of the disease was not a prerequisite for the initiation 
of OPA1 molecular genetic testing. 
Genomic DNA was extracted from venous blood samples using conventional protocols. PCR 
amplification and bidirectional Sanger sequencing of the OPA1 coding regions and intron-
exon boundaries was performed in probands as previously described (Thiselton et al. 2002). 
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DNA samples from available first degree relatives were also collected and used for targeted 
genetic testing of variants considered as potentially pathogenic. 
Sequence variants were described as per the Human Genome Variation Society 
recommendations (den Dunnen & Antonarakis 2000), and with reference to NG_011605.1 
and OPA1 transcript variant 8 (NCBI Reference Sequence: NM_130837.2) containing two 
additional exons 4b and 5b compared to transcript variant 1 (NM_015560.2) maintaining 
however the same reading frame and encoding a protein of 1015 amino acids.  
 
Interpretation of mutation pathogenicity 
Frequency of the changes detected in this study was searched in the following population 
databases: The Exome Aggregation Consortium (ExAC) (http://exac.braoadinstitute.org) 
showing exome sequencing data from more than 60,000 unrelated individuals and The Exome 
Variant Server (EVS, NHLBI Exome Sequencing Project; 
http://evs.gs.washington.edu/EVS/), which includes data from more than 6,000 individuals 
(both accessed 7 May 2016). Only rare variants (i.e. minor allele frequency ≤ 0.001) were 
further evaluated for potential pathogenicity. Identified sequence changes were further cross-
referenced with published literature and the eOPA1 mutational database (http://mitodyn.org, 
accessed December 2015). 
As it has been convincingly documented that reduction in OPA1 protein levels is a disease 
mechanism in DOA (Marchbank et al. 2002; Schimpf et al. 2008; Fuhrmann et al. 2009) 
variants predicted to lead to an absence of the gene product due to the mRNA nonsense-
mediated decay mechanism (e.g., nonsense or frameshifting mutations located 50-55 bp 
upstream from the last intron-exon junction) were considered as pathogenic. 
The pathogenicity of missense variants was predicted using various algorithms; Sorting 
Tolerant From Intolerant (SIFT) (Kumar et al. 2009), Polymorphism Phenotyping v2 
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(PolyPhen-2) (Adzhubei et al. 2010), MutPred (Li et al. 2009), Mutation Taster (Schwarz et 
al. 2010), SNPs&GO (Calabrese et al. 2009), PhD-SNP (Capriotti et al. 2006), PROVEAN 
(Choi et al. 2012) and Panther (Capriotti et al. 2006). Novel OPA1 missense variants with no 
entry in ExAC and EVS and predicted harmful by at least three tools were regarded as 
pathogenic. Heterozygous missense variants previously observed in DOA patients and not 
present in population databases were also considered pathogenic, regardless of their scoring 
by in silico algorithms. 
As cDNA was not available to experimentally evaluate whether canonical (±1 or 2), non-
canonical splice variants and coding variants close to intron-exon boundaries (i. e. +1, +2 or -
1, -2) affect pre-mRNA splicing, the wild-type and mutated sequences were analysed by 
splice site prediction tools Human Splicing Finder (Desmet et al. 2009), NNSPLICE (Reese et 
al. 1997), MaxEntScan (Yeo & Burge 2004) and NetGene2 (Brunak et al. 1991). Mutations 
leading to the disruption of splice site predicted by at least three out of the four tools used 
were considered pathogenic. Conservation analysis of affected amino acid residues across 16 
species was performed using T-coffee (Di Tommaso et al. 2011).  
Sequence variants not segregating with the disease-phenotype, i. e. not present in all affected 
members of a given family were considered benign. As penetrance of DOA maybe as low as 
43% (Toomes et al. 2001) the presence of a mutation in clinically unaffected family members 
was not considered to be excluding its pathogenic nature 
 
 
RESULTS 
Summary of the study cohort demographics and rare variants identified is provided in Table 1. 
In total, 32 rare sequence changes in a heterozygous state were detected in OPA1 coding 
region and intron-exon boundaries in 44 probands, out of 82 tested. Pathogenicity scores of 
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missense variants and effect predictions of variants potentially affecting splicing is provided 
in Supplementary Table 1 and 2, respectively. All novel pathogenic variants were submitted 
to the OPA1 locus specific database (http://opa1.mitodyn.org/) (Ferre et al. 2015). 
Altogether, 29 mutations observed in 42 probands were evaluated as pathogenic and three 
sequence variants were classified as being of unknown significance, of these one was present 
in a proband carrying a different OPA1 disease-causing mutation. The predicted and/or in 
previous studies already functionally verified effect of disease-causing variants was missense 
(n=7), splicing (n=11), nonsense (n=4) and frameshifting (n=7) (Table 1). 
Eight mutations identified are in bases of canonical dinucleotides at the splice-acceptor or 
splice-donor site. In addition, three other mutations found in the current study c.1035+5G>A, 
c.1305+5G>C and c.1148A>G were previously experimentally shown to cause a splicing 
defect (Baris et al. 2003; Schimpf et al. 2008). In silico analysis supported deleterious effect 
of 9 mutations on pre-mRNA splicing (Supplementary Table 2).  
Six mutations were found in more than one proband, c.1034G>A in two Czech and one UK 
proband, c.1035+5G>A in two UK probands, c.1673C>A in four UK probands, c.1681+1G>T 
in five UK probands, c.1943T>C in two UK probands, c.2873_2876del in one Czech and four 
UK probands. 
In three patients two rare variants were detected; p.(Leu327Pro) and p.(Ala602Glu) in 
proband 6; p.Leu411_Glu435del and p.(Leu785Phe) in proband 14; p.(Ser701*) and 
p.Val958Glyfs*3 in proband 33. Unfortunately, in families of probands 6 and 33 we were not 
able to determine whether these mutations were present on the same allele or in a compound 
heterozygous state due to the unavailability of DNA samples from other family members. In 
family of proband 14 targeted mutational screening of similarly affected proband’s mother 
confirmed their cis position. In silico analysis (Supplementary Table 1) suggested that 
p.(Leu785Phe) is of unknown significance therefore less likely to be disease-causing. 
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None of the identified 32 rare sequence OPA1 variants was found in the EVS database. Three 
pathogenic mutations and one variant of unknown significance had an entry in the ExAC 
database (Table 1).  
Altogether, 16 probands out of 39 did not report a family history of visual loss, in five 
probands this information was not available. Mutational screening and clinical evaluation in 
order to assess possible de novo occurrence and penetrance could be performed (due to 
sample unavailability) only in two first degree relatives from pedigrees of probands 8 and 14 
carrying c.1034G>A and c.1305+5G>C mutations, respectively. Both had signs of bilateral 
optic atrophy. 
DOA plus phenotype was documented in 3 individuals. Proband 13 carrying c.1230+1G>A 
noticed gradual visual loss since childhood and hearing loss since 23 years of age, which was 
confirmed by brain-stem auditory evoked potential examination. Analysis of cerebrospinal 
fluid at the age of 22 years revealed four positive oligoclonal bands of immunoglobulin G and 
slightly decreased protein level which is consistent with multiple sclerosis-like phenotype. 
The patient denied permission to undergo brain MRI. CT scan of the brain revealed only on 
the presence of bilateral optic atrophy. Proband 15 harbouring c.1367G>A had hearing loss, 
peripheral neuropathy and proband 44 with c.2965dup had hearing loss and peripheral 
sensitive axonal neuropathy. Interestingly, she reported that her mother also suffered from 
severe neurological impairment and that she was diagnosed with multiple sclerosis. 
Unfortunately, he mother could not be examined as she had died of cancer. In addition, 
proband 3 found to carry c.943C>T (classified as variant of unknown significance) was 
reportedly diagnosed elsewhere with peripheral neuropathy.  
 
DISCUSSION 
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Herein we report on rare OPA1 sequence variants identified in a large cohort of international 
patients (white British, Canadian, Czech and one proband of Czech Roma origin) with 
bilateral optic atrophy. Ten novel sequence changes were detected, of these seven were 
considered pathogenic and three as variants of unknown significance. Two probands carried 
two different pathogenic mutations. Similarly, to other studies aiming at the identification of 
the underlying cause of bilateral optic atrophy (Ferre et al. 2009), all probands with no 
paternal family history were pre-screened for common mitochondrial mutations associated 
with Leber hereditary optic atrophy prior to OPA1 screening.  
The great majority 22 (76%) of the detected 29 pathogenic mutations observed in 30 (71%) 
out of 42 probands (including one individual with two frameshifting mutations) were 
predicted to lead to unstable transcripts likely to be degraded by mRNA nonsense mediated 
decay cell mechanism (Pesch et al. 2001; Schimpf et al. 2006; Zanna et al. 2008) confirming 
that lack of functional protein product underlies the great majority of DOA cases (Pesch et al. 
2001; Marchbank et al. 2002). 
Only 7 pathogenic missense mutations in this study were found in 12 out 42 (29%) probands 
(including one individual with two different missense mutations). This correspond to 
frequency estimated in other studies concluding that about 30% of patients with DOA carry 
missense OPA1 mutations (Amati-Bonneau et al. 2008; Ferraris et al. 2008; Hudson et al. 
2008; Yu-Wai-Man et al. 2010).  
Two mutations c.1034G>A and c.1148A>G in near proximity to intron-exon boundaries (2nd 
exonic 3’ nucleotides) were predicted to lead to an amino acid substitution. While c.1034G>A 
was indeed experimentally verified by Schimpf et al to cause p.Arg345Gln (Schimpf et al. 
2006), c.1148A>G leads to in-frame skipping of exon 11 leading to p.Val346_Phe383del 
alteration at the protein level (Baris et al. 2003) highlighting the fact that interpretation of 
mutations needs always to be put into context of nucleotide position within the open reading 
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frame so that variants interfering with splicing process are not wrongly indicated as 
substitutions.  
In three patients two rare variants were detected; p.(Leu327Pro) and p.(Ala602Glu) in 
proband 6; p.Leu411_Glu435del and p.(Leu785Phe) in proband 14; p.(Ser701*) and 
p.Val958Glyfs*3 in proband 33. Unfortunately, in families of probands 6 and 33 we were not 
able to determine whether these mutations were present on the same allele or in a compound 
heterozygous state due to the unavailability of DNA samples from other family members. In 
family of proband 14 targeted mutational screening of similarly affected proband’s mother 
confirmed their cis position. In silico analysis (Supplementary Table 1) suggested that 
p.(Leu785Phe) is of unknown significance therefore less likely to be disease-causing. 
c.1935+3A>G previously reported as benign (Toomes et al. 2001) has been regarded as a 
variant of unknown significance as it has an entry in the ExAC data set (observed however 
only in 1 allele out of 120,536) and functional study could not be performed due to sample 
unavailability.  
The clear limitation of the current study is that the majority of first degree relatives were not 
available for our investigation; in part information on family history was also missing. 
Negative family history for DOA was reported by 38% of probands with pathogenic mutation 
in OPA1 which we attribute to de novo occurring changes and incomplete penetrance. Three 
previously reported mutations in association with DOA and one variant of unknown 
significance are recorded in ExAC database, each with an occurrence 1 allele out of ~120,000. 
As it has been shown that penetrance of OPA1 mutations may be as low as 43% (Toomes et 
al. 2001), in addition to mild phenotypes that may remain unnoticed if subjects do not 
undergo comprehensive neuro-ophthalmological examination, we think that the presence of 
these mutations in public datasets does not exclude their pathogenic nature. 
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Further limitations of this study were that results of examinations to assess extraocular 
neurodegenerative impairment and hearing loss were not available for all individuals tested. 
DOA plus phenotype was therefore documented in only 3 probands out of 42 with OPA1 
disease-causing mutations and in 1 proband with a missense variant classified as of unknown 
significance. Out the four sequence variants detected in our patients with DOA plus syndrome 
only p.(Gly456Asp) in Dynamin, GTPase domain has been previously reported to cause this 
phenotype (Leruez et al. 2013).  
Although the remaining probands were not aware of any other than visual symptoms, it needs 
to stressed out that mild forms of hearing impairment or peripheral neuropathy might have not 
been noticed as results of neurological examinations, electrophysiological studies, audiometry 
and brain magnetic resonance imaging were not available for all individuals.  
In summary, our study expands the OPA1 mutational spectrum and shows that the proportion 
of pathogenic variants leading to insufficient OPA1 protein expression level may be higher 
than it has anticipated to date.  
 
Acknowledgements 
We thank referring physicians and all family members who took part in this study. This work 
was supported by UNCE 204011, PRVOUK-P24/LF1/3 and GAUK 38515 programs of the 
Charles University in Prague, AZV 16-32341A and RVO-VFN 64165 grants from the 
Ministry of Health of the Czech Republic, and MRC Grant G0700949. 
12 
 
REFERENCES:  
Adzhubei IA, S Schmidt, L Peshkin, VE Ramensky, A Gerasimova, P Bork, AS Kondrashov 
& SR Sunyaev (2010): A method and server for predicting damaging missense 
mutations. Nat Methods 7: 248-249. 
Alexander C, M Votruba, UE Pesch, DL Thiselton, S Mayer, A Moore, M Rodriguez, U 
Kellner, B Leo-Kottler, G Auburger, SS Bhattacharya & B Wissinger (2000): OPA1, 
encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy 
linked to chromosome 3q28. Nat Genet 26: 211-215. 
Almind GJ, J Ek, T Rosenberg, H Eiberg, M Larsen, L LuCamp, K Brøndum-Nielsen & K 
Grønskov (2012): Dominant optic atrophy in Denmark – report of 15 novel mutations 
in OPA1, using a strategy with a detection rate of 90%. BMC Medical Genetics 13: 1-
7. 
Amati-Bonneau P, D Milea, D Bonneau, A Chevrollier, M Ferre, V Guillet, N Gueguen, D 
Loiseau, MA de Crescenzo, C Verny, V Procaccio, G Lenaers & P Reynier (2009): 
OPA1-associated disorders: phenotypes and pathophysiology. Int J Biochem Cell Biol 
41: 1855-1865. 
Amati-Bonneau P, ML Valentino, P Reynier, ME Gallardo, B Bornstein, A Boissiere, Y 
Campos, H Rivera, JG de la Aleja, R Carroccia, L Iommarini, P Labauge, D Figarella-
Branger, P Marcorelles, A Furby, K Beauvais, F Letournel, R Liguori, C La Morgia, P 
Montagna, M Liguori, C Zanna, M Rugolo, A Cossarizza, B Wissinger, C Verny, R 
Schwarzenbacher, MA Martin, J Arenas, C Ayuso, R Garesse, G Lenaers, D Bonneau 
& V Carelli (2008): OPA1 mutations induce mitochondrial DNA instability and optic 
atrophy 'plus' phenotypes. Brain 131: 338-351. 
Anikster Y, R Kleta, A Shaag, WA Gahl & O Elpeleg (2001): Type III 3-methylglutaconic 
aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): 
13 
 
identification of the OPA3 gene and its founder mutation in Iraqi Jews. Am J Hum 
Genet 69: 1218-1224. 
Barbet F, S Hakiki, C Orssaud, S Gerber, I Perrault, S Hanein, D Ducroq, JL Dufier, A 
Munnich, J Kaplan & JM Rozet (2005): A third locus for dominant optic atrophy on 
chromosome 22q. J Med Genet 42: e1. 
Baris O, C Delettre, P Amati-Bonneau, MO Surget, JF Charlin & A Catier (2003): Fourteen 
novel OPA1 mutations in autosomal dominant optic atrophy including two de novo 
mutations in sporadic optic atrophy. Hum Mutat 21. 
Bertholet AM, AM Millet, O Guillermin, M Daloyau, N Davezac, MC Miquel & P Belenguer 
(2013): OPA1 loss of function affects in vitro neuronal maturation. Brain 136: 1518-
1533. 
Brunak S, J Engelbrecht & S Knudsen (1991): Prediction of human mRNA donor and 
acceptor sites from the DNA sequence. J Mol Biol 220: 49-65. 
Calabrese R, E Capriotti, P Fariselli, PL Martelli & R Casadio (2009): Functional annotations 
improve the predictive score of human disease-related mutations in proteins. Hum 
Mutat 30: 1237-1244. 
Capriotti E, R Calabrese & R Casadio (2006): Predicting the insurgence of human genetic 
diseases associated to single point protein mutations with support vector machines and 
evolutionary information. Bioinformatics 22: 2729-2734. 
Carelli V, S Schimpf, N Fuhrmann, ML Valentino, C Zanna & L Iommarini (2011): A 
clinically complex form of dominant optic atrophy (OPA8) maps on chromosome 16. 
Hum Mol Genet 20: 1893-1905. 
Carelli V, O Musumeci, L Caporali, C Zanna, C La Morgia, V Del Dotto, AM Porcelli, M 
Rugolo, ML Valentino, L Iommarini, A Maresca, P Barboni, M Carbonelli, C 
Trombetta, EM Valente, S Patergnani, C Giorgi, P Pinton, G Rizzo, C Tonon, R Lodi, 
14 
 
P Avoni, R Liquori, A Baruzzi, A Toscano & M Zeviani (2015): Syndromic 
parkinsonism and dementia associated with OPA1 missense mutations. Ann Neurol 
78: 21-38. 
Delettre C, JM Griffoin, J Kaplan, H Dollfus, B Lorenz & L Faivre (2001): Mutation 
spectrum and splicing variants in the OPA1 gene. Hum Genet 109. 
Delettre C, G Lenaers, JM Griffoin, N Gigarel, C Lorenzo, P Belenguer, L Pelloquin, J 
Grosgeorge, C Turc-Carel, E Perret, C Astarie-Dequeker, L Lasquellec, B Arnaud, B 
Ducommun, J Kaplan & CP Hamel (2000): Nuclear gene OPA1, encoding a 
mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat 
Genet 26: 207-210. 
den Dunnen JT & SE Antonarakis (2000): Mutation nomenclature extensions and suggestions 
to describe complex mutations: a discussion. Hum Mutat 15: 7-12. 
Desmet FO, D Hamroun, M Lalande, G Collod-Beroud, M Claustres & C Beroud (2009): 
Human Splicing Finder: an online bioinformatics tool to predict splicing signals. 
Nucleic Acids Res 37: e67. 
Di Tommaso P, S Moretti, I Xenarios, M Orobitg, A Montanyola, JM Chang, JF Taly & C 
Notredame (2011): T-Coffee: a web server for the multiple sequence alignment of 
protein and RNA sequences using structural information and homology extension. 
Nucleic Acids Res 39: W13-17. 
Ferraris S, S Clark, E Garelli, G Davidzon, SA Moore, RH Kardon, RJ Bienstock, MJ 
Longley, M Mancuso, P Gutierrez Rios, M Hirano, WC Copeland & S DiMauro 
(2008): Progressive external ophthalmoplegia and vision and hearing loss in a patient 
with mutations in POLG2 and OPA1. Arch Neurol 65: 125-131. 
15 
 
Ferre M, D Bonneau, D Milea, A Chevrollier, C Verny & H Dollfus (2009): Molecular 
screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 
novel OPA1 mutations. Hum Mutat 30: E692-705. 
Ferre M, A Caignard, D Milea, S Leruez, J Cassereau, A Chevrollier, P Amati-Bonneau, C 
Verny, D Bonneau, V Procaccio & P Reynier (2015): Improved locus-specific 
database for OPA1 mutations allows inclusion of advanced clinical data. Hum Mutat 
36: 20-25. 
Fuhrmann N, MV Alavi, P Bitoun, S Woernle, G Auburger, B Leo-Kottler, P Yu-Wai-Man, P 
Chinnery & B Wissinger (2009): Genomic rearrangements in OPA1 are frequent in 
patients with autosomal dominant optic atrophy. J Med Genet 46: 136-144. 
Gallus GN, E Cardaioli, A Rufa, M Collura, P Da Pozzo, E Pretegiani, M Tumino, L Pavone 
& A Federico (2012): High frequency of OPA1 mutations causing high ADOA 
prevalence in south-eastern Sicily, Italy. Clin Genet 82: 277-282. 
Hudson G, P Amati-Bonneau, EL Blakely, JD Stewart, L He, AM Schaefer, PG Griffiths, K 
Ahlqvist, A Suomalainen, P Reynier, R McFarland, DM Turnbull, PF Chinnery & RW 
Taylor (2008): Mutation of OPA1 causes dominant optic atrophy with external 
ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel 
disorder of mtDNA maintenance. Brain 131: 329-337. 
Cho DH, T Nakamura & SA Lipton (2010): Mitochondrial dynamics in cell death and 
neurodegeneration. Cell Mol Life Sci 67: 3435-3447. 
Choi Y, GE Sims, S Murphy, JR Miller & AP Chan (2012): Predicting the functional effect of 
amino acid substitutions and indels. PLoS One 7: e46688. 
Ke T, SW Nie, QB Yang, JP Liu, LN Zhou, X Ren, JY Liu, Q Wang & MG Liu (2006): The 
G401D mutation of OPA1 causes autosomal dominant optic atrophy and hearing loss 
in a Chinese family. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 23: 481-485. 
16 
 
Kerrison JB, VJ Arnould, JM Ferraz Sallum, MR Vagefi, MM Barmada, Y Li, D Zhu & IH 
Maumenee (1999): Genetic heterogeneity of dominant optic atrophy, Kjer type: 
Identification of a second locus on chromosome 18q12.2-12.3. Arch Ophthalmol 117: 
805-810. 
Kim JY, JM Hwang, HS Ko, MW Seong, BJ Park & SS Park (2005): Mitochondrial DNA 
content is decreased in autosomal dominant optic atrophy. Neurology 64: 966-972. 
Kjer B, H Eiberg, P Kjer & T Rosenberg (1996): Dominant optic atrophy mapped to 
chromosome 3q region. II. Clinical and epidemiological aspects. Acta Ophthalmol 
Scand 74. 
Kumar P, S Henikoff & PC Ng (2009): Predicting the effects of coding non-synonymous 
variants on protein function using the SIFT algorithm. Nat Protoc 4: 1073-1081. 
Leruez S, D Milea, S Defoort-Dhellemmes, E Colin, M Crochet, V Procaccio, M Ferre, J 
Lamblin, V Drouin, C Vincent-Delorme, G Lenaers, C Hamel, C Blanchet, G Juul, M 
Larsen, C Verny, P Reynier, P Amati-Bonneau & D Bonneau (2013): Sensorineural 
hearing loss in OPA1-linked disorders. Brain 136: e236. 
Li B, VG Krishnan, ME Mort, F Xin, KK Kamati, DN Cooper, SD Mooney & P Radivojac 
(2009): Automated inference of molecular mechanisms of disease from amino acid 
substitutions. Bioinformatics 25: 2744-2750. 
Liskova P, O Ulmanova, P Tesina, H Melsova, P Diblik, H Hansikova, M Tesarova & M 
Votruba (2013): Novel OPA1 missense mutation in a family with optic atrophy and 
severe widespread neurological disorder. Acta Ophthalmol 91: e225-231. 
Lunkes A, U Hartung, C Magarino, M Rodriguez, A Palmero, L Rodriguez, L Heredero, J 
Weissenbach, J Weber & G Auburger (1995): Refinement of the OPA1 gene locus on 
chromosome 3q28-q29 to a region of 2-8 cM, in one Cuban pedigree with autosomal 
dominant optic atrophy type Kjer. Am J Hum Genet 57: 968-970. 
17 
 
Lyle W (ed.) (1990): Genetic risks. Waterloo, Ontario. University of Waterloo Press. 
Manners DN, G Rizzo, C La Morgia, C Tonon, C Testa, P Barboni, E Malucelli, ML 
Valentino, L Caporali, D Strobbe, V Carelli & R Lodi (2015): Diffusion Tensor 
Imaging Mapping of Brain White Matter Pathology in Mitochondrial Optic 
Neuropathies. AJNR Am J Neuroradiol 36: 1259-1265. 
Marchbank NJ, JE Craig, JP Leek, M Toohey, AJ Churchill, AF Markham, DA Mackey, C 
Toomes & CF Inglehearn (2002): Deletion of the OPA1 gene in a dominant optic 
atrophy family: evidence that haploinsufficiency is the cause of disease. J Med Genet 
39: e47. 
Murton NJ, L French, C Toomes, SS Joseph, I Rehman, BL Hopkins, CF Inglehearn & AJ 
Churchill (2001): A high-density transcript map of the human dominant optic atrophy 
OPA1 gene locus and re-evaluation of evidence for a founder haplotype. Cytogenet 
Cell Genet 92: 97-102. 
Olichon A, T Landes, L Arnaune-Pelloquin, LJ Emorine, V Mils, A Guichet, C Delettre, C 
Hamel, P Amati-Bonneau, D Bonneau, P Reynier, G Lenaers & P Belenguer (2007): 
Effects of OPA1 mutations on mitochondrial morphology and apoptosis: relevance to 
ADOA pathogenesis. J Cell Physiol 211: 423-430. 
Pesch UE, B Leo-Kottler, S Mayer, B Jurklies, U Kellner, E Apfelstedt-Sylla, E Zrenner, C 
Alexander & B Wissinger (2001): OPA1 mutations in patients with autosomal 
dominant optic atrophy and evidence for semi-dominant inheritance. Hum Mol Genet 
10: 1359-1368. 
Puomila A, K Huoponen, M Mantyjarvi, P Hamalainen, R Paananen, EM Sankila, ML 
Savontaus, M Somer & E Nikoskelainen (2005): Dominant optic atrophy: correlation 
between clinical and molecular genetic studies. Acta Ophthalmol Scand 83: 337-346. 
18 
 
Reese MG, FH Eeckman, D Kulp & D Haussler (1997): Improved splice site detection in 
Genie. J Comput Biol 4: 311-323. 
Reynier P, P Amati-Bonneau, C Verny, A Olichon, G Simard, A Guichet, C Bonnemains, F 
Malecaze, MC Malinge, JB Pelletier, P Calvas, H Dollfus, P Belenguer, Y Malthiery, 
G Lenaers & D Bonneau (2004): OPA3 gene mutations responsible for autosomal 
dominant optic atrophy and cataract. J Med Genet 41: e110. 
Rönnbäck C, C Nissen, GJ Almind, K Gronskov, D Milea, M Larsen (2015): Genotype-
phenotype heterogeneity of ganglion cell and inner plexiform layer deficit in 
autosomal-dominant optic atrophy. Acta Ophthalmol 93: 762-766. 
Russo A, L Delcassi, E Marchina & F Semeraro (2013): Correlation between visual acuity 
and OCT-measured retinal nerve fiber layer thickness in a family with ADOA and an 
OPA1 mutation. Ophthalmic Genet 34: 69-74. 
Schimpf S, N Fuhrmann, S Schaich & B Wissinger (2008): Comprehensive cDNA study and 
quantitative transcript analysis of mutant OPA1 transcripts containing premature 
termination codons. Hum Mutat 29: 106-112. 
Schimpf S, S Schaich & B Wissinger (2006): Activation of cryptic splice sites is a frequent 
splicing defect mechanism caused by mutations in exon and intron sequences of the 
OPA1 gene. Hum Genet 118. 
Schwarz JM, C Rodelsperger, M Schuelke & D Seelow (2010): MutationTaster evaluates 
disease-causing potential of sequence alterations. Nat Methods 7: 575-576. 
Thiselton DL, C Alexander, JW Taanman, S Brooks, T Rosenberg & H Eiberg (2002): A 
comprehensive survey of mutations in the OPA1 gene in patients with autosomal 
dominant optic atrophy. Invest Ophthalmol Vis Sci 43. 
Toomes C, NJ Marchbank, DA Mackey, JE Craig, RA Newbury-Ecob, CP Bennett, CJ Vize, 
SP Desai, GC Black, N Patel, M Teimory, AF Markham, CF Inglehearn & AJ 
19 
 
Churchill (2001): Spectrum, frequency and penetrance of OPA1 mutations in 
dominant optic atrophy. Hum Mol Genet 10: 1369-1378. 
Votruba M, AT Moore & SS Bhattacharya (1997): Genetic refinement of dominant optic 
atrophy (OPA1) locus to within a 2 cM interval of chromosome 3q. J Med Genet 34: 
117-121. 
Votruba M, AT Moore & SS Bhattacharya (1998): Clinical features, molecular genetics, and 
pathophysiology of dominant optic atrophy. J Med Genet 35: 793-800. 
Yeo G & CB Burge (2004): Maximum entropy modeling of short sequence motifs with 
applications to RNA splicing signals. J Comput Biol 11: 377-394. 
Yu-Wai-Man P, PG Griffiths, A Burke, PW Sellar, MP Clarke, L Gnanaraj, D Ah-Kine, G 
Hudson, B Czermin, RW Taylor, R Horvath & PF Chinnery (2010): The prevalence 
and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmology 
117: 1538-1546, 1546 e1531. 
Yu-Wai-Man P, PG Griffiths, G Hudson & PF Chinnery (2009): Inherited mitochondrial optic 
neuropathies. J Med Genet 46: 145-158. 
Yu-Wai-Man P, SP Shankar, V Biousse, NR Miller, LJ Bean, B Coffee, M Hegde & NJ 
Newman (2011): Genetic screening for OPA1 and OPA3 mutations in patients with 
suspected inherited optic neuropathies. Ophthalmology 118: 558-563. 
Zanna C, A Ghelli, AM Porcelli, M Karbowski, RJ Youle, S Schimpf, B Wissinger, M Pinti, 
A Cossarizza, S Vidoni, ML Valentino, M Rugolo & V Carelli (2008): OPA1 
mutations associated with dominant optic atrophy impair oxidative phosphorylation 
and mitochondrial fusion. Brain 131: 352-367. 
 
 
